GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forte Biosciences Inc (NAS:FBRX) » Definitions » Forward PE Ratio

Forte Biosciences (Forte Biosciences) Forward PE Ratio : 0.00 (As of May. 26, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Forte Biosciences Forward PE Ratio?

Forte Biosciences's Forward PE Ratio for today is 0.00.

Forte Biosciences's PE Ratio without NRI for today is 0.00.

Forte Biosciences's PE Ratio for today is 0.00.


Forte Biosciences Forward PE Ratio Historical Data

The historical data trend for Forte Biosciences's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forte Biosciences Forward PE Ratio Chart

Forte Biosciences Annual Data
Trend
Forward PE Ratio

Forte Biosciences Quarterly Data
Forward PE Ratio

Competitive Comparison of Forte Biosciences's Forward PE Ratio

For the Biotechnology subindustry, Forte Biosciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Forte Biosciences's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forte Biosciences's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Forte Biosciences's Forward PE Ratio falls into.



Forte Biosciences Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Forte Biosciences  (NAS:FBRX) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Forte Biosciences Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Forte Biosciences's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Forte Biosciences (Forte Biosciences) Business Description

Traded in Other Exchanges
Address
3060 Pegasus Park Drive, Building 6, Dallas, TX, USA, 75247
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease ("GvHD"), vitiligo and alopecia areata ("AA"). The company is developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric patients with atopic dermatitis. It plans to advance FB-401 into a randomized Phase 2 clinical trial.
Executives
Paul A. Wagner director, officer: See Remarks C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
Scott C. Brun director C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Hubert C Chen officer: See remarks C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Stephen K Doberstein director 129 ELSIE STREET, SAN FRANCISCO CA 94110
Barbara K Finck director C/O PROTINE DESIGN LAB, 3858 JACKSON ST, SAN FRANCISCO CA 94118
Antony A Riley officer: Chief Financial Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 94538
Thomas E Darcy director C/O SCIENCE APPLICATIONS INTL CORP, 10260 CAMPUS POINT DR., SAN DIEGO CA 92121
Donald Allen Williams director C/O PRYOR CASHMAN LLP, 7 TIMES SQUARE, NEW YORK NY 10036
Patricia S Walker director 5540 EKWILL ST STE D, SANTA BARBARA CA 93111
Lawrence Eichenfield director C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502
Steven Kornfeld director C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502
Steven Michael Oliveira 10 percent owner 18 FIELDSTONE COURT, NEW CITY NY 10956
Fairooz Kabbinavar officer: SVP Clinical Development C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121
Mark G Foletta officer: EVP & Chief Financial Officer AMYLIN PHARMACEUTICALS INC, 9360 TOWNE CENTRE DR, SAN DIEGO CA 92121